Adjuvant Dual HER2-Targeted Therapy for HER2+ Early-Stage Breast Cancer
Adjuvant Dual HER2-Targeted Therapy for HER2+ Early-Stage Breast Cancer
- A 49-year-old women was referred for biopsy after routine mammography showed a 2.4-cm diameter spiculated mass in the left breast
- PE: revealed a well-circumscribed, non-tender firm mass in the lower-outer quadrant of the left breast; singular palpable nodal enlargement in the left axilla
- Excisional biopsy of the breast and axillary lymph nodes showed high grade lobular carcinoma
- ER-/PR-; HER2 IHC 3+; Ki-67, 89%
- Staging, pT2N3M0
- She underwent right mastectomy and lymph node dissection
- The patient was started on adjuvant chemotherapy with docetaxel + carboplatin with 12 months of trastuzumab + pertuzumab
Related Videos
Related Content
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020Podcast
In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer
March 20th 2024Article
Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.
Read More
